Grifols (GIFLF) Other Accumulated Expenses (2010 - 2021)
Grifols (GIFLF) reported Other Accumulated Expenses of $250.8 million for Q4 2021, up 37.36% on a YoY basis from $182.6 million in Q4 2020, and up 37.36% quarter-over-quarter from $182.6 million in Q4 2020.
Grifols (GIFLF) Other Accumulated Expenses (2010 - 2021) Analysis & Trends
Grifols has reported Other Accumulated Expenses for 12 years, with the latest figure at $250.8 million in Q4 2021.
- For the quarter ending Q4 2021, Other Accumulated Expenses rose 37.36% year-over-year to $250.8 million; the trailing twelve-month figure through Dec 2021 stood at $250.8 million (up 37.36% YoY), and the FY2021 full-year result was $250.8 million, up 37.36% from the prior year.
- Other Accumulated Expenses for Q4 2021 stood at $250.8 million, up from $182.6 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $1.1 billion in Q4 2018, with the low at $141.5 million in Q2 2017.
- Historically, Other Accumulated Expenses has averaged $773.3 million across 5 years, with a median of $1.0 billion in 2018.
- Annual changes were most pronounced in 2017 — Other Accumulated Expenses surged 540.14% — and 2020, when it plunged 83.59%.
- Grifols' Other Accumulated Expenses stood at $968.9 million in 2017, then increased by 15.44% to $1.1 billion in 2018, then retreated by 0.52% to $1.1 billion in 2019, then tumbled by 83.59% to $182.6 million in 2020, then jumped by 37.36% to $250.8 million in 2021.
- The last three Other Accumulated Expenses figures came in at $250.8 million (Q4 2021), $182.6 million (Q4 2020), and $1.1 billion (Q3 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 250.84 Mn |
| Dec 31, 2020 | 182.61 Mn |
| Sep 30, 2020 | 1.08 Bn |
| Mar 31, 2020 | 1.11 Bn |
| Dec 31, 2019 | 1.11 Bn |
| Sep 30, 2019 | 1.09 Bn |
| Dec 31, 2018 | 1.12 Bn |
| Sep 30, 2018 | 975.69 Mn |
| Jun 30, 2018 | 165.40 Mn |
| Mar 31, 2018 | 1.09 Bn |
| Dec 31, 2017 | 968.93 Mn |
| Jun 30, 2017 | 141.55 Mn |
| Dec 31, 2016 | 151.36 Mn |
| Sep 30, 2016 | 133.26 Mn |
| Jun 30, 2016 | 125.37 Mn |
| Dec 31, 2015 | 147.61 Mn |
| Sep 30, 2015 | 150.33 Mn |
| Jun 30, 2015 | 139,030.09 |
| Mar 31, 2015 | 138.08 Mn |
| Dec 31, 2014 | 184.83 Mn |